• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·6810.TWO
Share

Bio Preventive Medicine Corp. Stocks

NT$ 21.25Last Updated 19.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

NT$ 32.94M

NT$ 21.25
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Bio Preventive Medicine Corp., a biotechnology firm currently in the clinical development phase, specializes in the proactive identification and mitigation of various illnesses. The company develops comprehensive strategies for the prevention, screening, and ongoing oversight of chronic conditions and cancer treatment. A key offering is the DNlite test, a suite of proprietary and medically validated non-intrusive urine analyses designed to aid in the management of diabetic kidney disease, encompassing specific products like DNlite-IVD103 and DNlite-DN_Score. Established in 2014, its main operations are located in Zhubei, Taiwan.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

19.10.2026 15:56

After the elections, French markets face a more serious test—the City. What should investors do?

19.10.2026 15:19

An analyst has identified a new driver for Victoria's Secret's stock: weight-loss products

19.10.2026 14:45

Fears surrounding AI are bringing treasury back into a defensive role. What should investors be prepared for?

19.10.2026 14:11

Musk promised to give SpaceX stock to “every child in America”

19.10.2026 13:25

Burry Compared the Next Crash to a Supervolcano Eruption: 5 Signs for Investors

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026